TW200714596A - Isotopically substituted proton pump inhibitors - Google Patents

Isotopically substituted proton pump inhibitors

Info

Publication number
TW200714596A
TW200714596A TW095127340A TW95127340A TW200714596A TW 200714596 A TW200714596 A TW 200714596A TW 095127340 A TW095127340 A TW 095127340A TW 95127340 A TW95127340 A TW 95127340A TW 200714596 A TW200714596 A TW 200714596A
Authority
TW
Taiwan
Prior art keywords
proton pump
pump inhibitors
isotopically substituted
substituted proton
isotopically
Prior art date
Application number
TW095127340A
Other languages
Chinese (zh)
Other versions
TWI394750B (en
Inventor
Bernhard Kohl
Bernd Muller
Dieter Haag
Wolfgang-Alexander Simon
Karl Zech
Michael David
Richter Oliver Von
Felix Huth
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of TW200714596A publication Critical patent/TW200714596A/en
Application granted granted Critical
Publication of TWI394750B publication Critical patent/TWI394750B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/69Two or more oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention relates to benzimidazoles of formula 1 and to pharmaceutical compositions comprising these compounds, further to intermediates of formula 2 and 3.
TW095127340A 2005-07-26 2006-07-26 Isotopically substituted proton pump inhibitors TWI394750B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05106868 2005-07-26

Publications (2)

Publication Number Publication Date
TW200714596A true TW200714596A (en) 2007-04-16
TWI394750B TWI394750B (en) 2013-05-01

Family

ID=35734406

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095127340A TWI394750B (en) 2005-07-26 2006-07-26 Isotopically substituted proton pump inhibitors

Country Status (16)

Country Link
EP (1) EP1910293A1 (en)
JP (1) JP5448448B2 (en)
KR (1) KR101358509B1 (en)
CN (2) CN102134232B (en)
AR (1) AR054584A1 (en)
AU (1) AU2006274036B2 (en)
BR (1) BRPI0614039A2 (en)
CA (1) CA2615670C (en)
EA (1) EA016814B1 (en)
IL (1) IL188773A (en)
MX (1) MX2008000901A (en)
NO (1) NO20080839L (en)
NZ (1) NZ565078A (en)
TW (1) TWI394750B (en)
WO (1) WO2007012650A1 (en)
ZA (1) ZA200800303B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006274037B2 (en) * 2005-07-26 2012-04-26 Takeda Gmbh Isotopically substituted pantoprazole
EP1934201A1 (en) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US20080255200A1 (en) * 2007-04-11 2008-10-16 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles
WO2008127640A2 (en) * 2007-04-11 2008-10-23 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles
CA2789298A1 (en) 2010-02-12 2011-08-18 Esteve Quimica, S.A. Preparation process of the sodium salt of esomeprazole
CN104530003A (en) * 2014-06-10 2015-04-22 广东东阳光药业有限公司 Preparation method of salt of pyridylmethylsulfinyl-1H-benzimidazole compound

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (en) * 1978-04-14 1979-10-15 Haessle Ab Gastric acid secretion
JPH0643426B2 (en) * 1986-07-25 1994-06-08 東京田辺製薬株式会社 Imidazo [4,5-b] pyridine derivative, method for producing the same, and antiulcer agent containing the same
ES2293638T3 (en) * 1994-03-25 2008-03-16 Isotechnika, Inc. IMPROVEMENT OF THE EFFECTIVENESS OF PHARMACOS BY DEUTERATION.
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6884429B2 (en) * 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
NO309305B1 (en) * 1999-02-19 2001-01-15 Norsk Hydro As Use of benzaldehyde derivatives in the manufacture of pharmaceutical preparations for the prevention and / or treatment of cancer, as well as certain new benzaldehyde derivatives
DE10123129A1 (en) * 2001-05-02 2002-11-14 Berolina Drug Dev Ab Svedala Deuterated 3-piperidinopropiophenones and medicinal products containing these compounds
DE10162121A1 (en) * 2001-12-12 2003-06-18 Berolina Drug Dev Ab Svedala Deuterated substituted pyrazolyl-benzenesulfonamides and drugs containing these compounds
AU2006274037B2 (en) * 2005-07-26 2012-04-26 Takeda Gmbh Isotopically substituted pantoprazole

Also Published As

Publication number Publication date
AU2006274036A1 (en) 2007-02-01
IL188773A (en) 2014-02-27
AU2006274036B2 (en) 2012-05-24
AU2006274036A2 (en) 2008-03-20
ZA200800303B (en) 2009-01-28
KR101358509B1 (en) 2014-02-05
NZ565078A (en) 2010-03-26
CA2615670C (en) 2015-01-20
CN101268051A (en) 2008-09-17
CN102134232B (en) 2012-11-21
CN102134232A (en) 2011-07-27
EP1910293A1 (en) 2008-04-16
CN101268051B (en) 2011-08-31
HK1160126A1 (en) 2012-08-10
KR20080037676A (en) 2008-04-30
JP5448448B2 (en) 2014-03-19
WO2007012650A1 (en) 2007-02-01
HK1125098A1 (en) 2009-07-31
NO20080839L (en) 2008-02-18
AR054584A1 (en) 2007-06-27
EA016814B1 (en) 2012-07-30
TWI394750B (en) 2013-05-01
MX2008000901A (en) 2008-03-26
CA2615670A1 (en) 2007-02-01
BRPI0614039A2 (en) 2011-03-09
EA200800203A1 (en) 2008-08-29
IL188773A0 (en) 2008-08-07
JP2009502871A (en) 2009-01-29

Similar Documents

Publication Publication Date Title
MY153915A (en) Organic compounds
DE602004008098D1 (en) SUBSTITUTED 2H-Ä1,2,4ÜTRIAZOLOÄ4,3-AÜPYRAZINE AS GSK-3 INHIBITORS
MY148634A (en) Pyridazinone derivatives
TW200610531A (en) Phthalazine derivatives as PARP inhibitors
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
DK1853602T3 (en) Chemical compounds
CY1108275T1 (en) CHEMICAL COMPOUNDS
UA94833C2 (en) Substituted bicyclolactams
CY1109911T1 (en) PYRROLOVENZODIAZEPINES
EA200900828A1 (en) COMPOUNDS AND COMPOSITIONS AS AN INHIBITOR ACTIVITY OF THE CANANABINOID RECEPTOR 1
MX2009004746A (en) 1,2,4-triazole derivatives as sigma receptor inhibitors.
MX2007011023A (en) 2- (4-0x0-4h-quinaz0lin-3-yl) acetamides and their use as vasopressin v3 antagonists.
EA200901124A1 (en) COMPOUNDS OF FORMULA (I) AS SERINPROTEASE INHIBITORS
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
HRP20080529T3 (en) Amide prodrug of gemcitabine, compositions and use thereof
SG158091A1 (en) Imidazoazepinone compounds
WO2006047415A3 (en) FACTOR Xa COMPOUNDS
TW200745122A (en) New compounds I
NO20080839L (en) Isotope-substituted proton pump inhibitors
TW200745039A (en) Isotopically substituted pantoprazole
TR201109686T2 (en) Pharmaceutical Compositions of Olmesartan.
MY150988A (en) Novel derivatives of ( bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors
ATE417849T1 (en) PYRAZOLOA4,3-DÜPYRIMIDINE
EA200801366A1 (en) DERIVATIVES 3,6-DIGIDRO-2-OXO-6N-1,3,4-TIADIAZINA
DE602007005387D1 (en) PTORS

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees